Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mileutis Ltd. has 1 pending office action focused in the Biotechnology & Pharmaceuticals technology area. The current prosecution footprint is limited to 1 distinct examiner and 1 distinct art unit, showing a narrow administrative scope for the company's active matters. This suggests that the company is currently advancing a specific biotechnological innovation through 1 specialized channel at the patent office. This focus can be beneficial for maintaining a consistent narrative across the application's claims.
JAUHARI, SACHI is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This examiner is responsible for the company's current pending workload, making their individual examination style the primary factor in the progress of these Biotechnology & Pharmaceuticals applications. Without other active examiners or art units involved, the company's short-term patenting goals are entirely dependent on the resolution of the issues raised by this 1 official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557393 | COMPOSITIONS AND METHODS FOR MODULATING MAMMARY DISORDERS AND CONDITIONS | JAUHARI, SACHI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557393 | COMPOSITIONS AND METHODS FOR MODULATING MAMMARY DISORDERS AND CONDITIONS | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557393 | COMPOSITIONS AND METHODS FOR MODULATING MAMMARY DISORDERS AND CONDITIONS | JAUHARI, SACHI | 1654 | §101§103§112Other | Non-Final OA | — | Pending | Oct 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMileutis Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Sachi Jauhari has the most, with 1 of Mileutis Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.